Mucosal barrier injury: Biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: An overview

Bone Marrow Transplantation

Volumn 25, Issue 12, 2000, Pages 1269-1278

  Blijlevens, N M A ^a   Donnelly, J P ^a   De Pauw, B E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnosis; Mucosal barrier injury; Mucositis; Risk factors; Treatment

Indexed keywords

ANTIINFECTIVE AGENT; BLEOMYCIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC AGENT; ENDOTOXIN; FLUOROURACIL;

ARTICLE; DIGESTIVE SYSTEM ULCER; EPITHELIUM; GRAFT VERSUS HOST REACTION; HEALING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION COMPLICATION; INTESTINE MUCOSA; LEUKEMIA; MICROFLORA; MOUTH MUCOSA; MUCOSA INFLAMMATION; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; VEIN OCCLUSION;

EID: 0033935706     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702447     Document Type: Article

References (123)

1. Berger AM, Kilroy TJ. Adverse effects of treatment; oral complications. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer; Principles and Practice of Oncology, 5th edn. Lippincott-Raven Publishers: Philadelphia, 1997, pp 2714-2725.
2. Schubert MM, Williams BE, Lloid ME et al. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 1992; 69: 2469-2477.
3. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72: 1612-1617.
4. Parulekar W, Mackenzie R, Bjarnason G, Jordan RC. Scoring oral mucositis. Oral Oncol 1998; 34: 63-71.
5. Donnelly JP, Muus P, Schattenberg A et al. A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant 1992; 9: 409-413.
6. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34: 39-43.
7. Sleisenger MH, Fordtran JS. Gastrointestinal Disease; Pathophysiology, Diagnosis, Management, 4th edn. WB Saunders Company: Philadelphia, 1989.
8. Sherman ML, Datta R, Hallahan DE et al. Regulation of tumor necrosis factor gene expression by ionizing radiation in human myeloid leukemia cells and peripheral blood monocytes. J Clin Invest 1991; 87: 1794-1797.
9. Hoffmann B, Hintermeier-Knabe R, Holler E et al. Evidence for induction of TNFa by irradiation and cytotoxic therapy preceding bone marrow transplantation - in vivo and in vitro studies. Eur Cytokine Netw 1992; 3: 256.
10. Ferrara JL. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 1993; 5: 794-799.
11. Sonis ST, Tracey C, Shklar G et al. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1990; 69: 437-443.
12. Schwaighofer H, Kernan NA, O'Reilly RJ et al. Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation: influence of conditioning and hematopoietic reconstitution. Transplantation 1996; 62: 947-953.
13. Hill GR, Crawford JM, Cooke KR et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
14. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
15. Niederwieser D, Herold M, Woloszczuk W et al. Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 1990; 50: 620-625.
16. Holler E, Kolb HJ, Mittermuller J et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890-899.
17. Chasty RC, Lamb WR, Gallati H et al. Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993; 12: 331-336.
18. Schwaighofer H, Herold M, Schwarz T et al. Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation 1994; 58: 430-436.
19. Adams RB, Planchon SM, Roche JK. IFN-gamma modulation of epithelial barrier function. Time course, reversibility, and site of cytokine binding. J Immunol 1993; 150: 2356-2363.
20. Austgen TR, Chen MK, Dudrick PS et al. Cytokine regulation of intestinal glutamine utilisation. Am J Surg 1992; 163: 174-179.
21. Marano CW, Lewis SA, Garulacan LA et al. Tumor necrosis factor-alpha increases sodium and chloride conductance across the tight junction of CACO-2 BBE, a human intestinal epithelial cell line. J Membr Biol 1998; 161: 263-274.
22. Souba WW, Copeland EM. Cytokine modulation of Na(+)-dependent glutamine transport across the brush border membrane of monolayers of human intestinal Caco-2 cells. Ann Surg 1992; 215: 536-544.
23. Jarry A, Muzeau F, Laboisse C. Cytokine effects in a human colonic goblet cell line. Cellular damage and its partial prevention by 5 aminosalicylic acid. Dig Dis Sci 1992; 37: 1170-1178.
24. Fox PC, Grisius MM, Bermudez, DK, Sun D. Cytokine mRNA expression in labial salivary glands and cytokine secretion in parotid saliva in Sjogren's syndrome. Adv Exp Med Biol 1998; 438: 909-915.
25. Xun CQ, Thompson JS, Jennings CD et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.
26. Goke M, Podolsky DK. Regulation of the mucosal epithelial barrier. Baillieres Clin Gastroenterol 1996; 10: 393-405.
27. Wright NA. Aspects of the biology of regeneration and repair in the human gastrointestinal tract. Philos Trans R Soc Lond B Biol Sci 1998; 353: 925-933.
28. Steel G. Combination of radiotherapy and chemotherapy. In Steel G (ed). Basic Clinical Radiobiology; for Radiation Oncologists. Edward Arnold: London, 1993, pp 151-162.
29. Muus P, Donnelly P, Schattenberg A et al. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. Semin Oncol 1993; 20(Suppl. 8): 47-52.
30. Shaw MT, Spector MH, Ladman AJ. Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function. Cancer Treat Rev 1979; 6: 141-151.
31. McNabb PC, Tomasi TB. Host defense mechanisms at mucosal surfaces. Annu Rev Microbiol 1981; 35: 477-496
32. Mestecky J, Russell MW, Elson CO. Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Gut 1999; 44: 2-5.
33. Ganz T, Lehrer RI. Defensins. Pharmacol Ther 1995; 66: 191-205.
34. Garfunkel AA, Tager N, Chausu S et al. Oral complications in bone marrow transplantation patients: recent advances. Isr J Med Sci 1994; 30: 120-124.
35. Meurman JH, Pyrhonen S, Teerenhovi L, Lindqvist C. Oral sources of septicaemia in patients with malignancies. Oral Oncol 1997; 33: 389-397.
36. Ruescher TJ, Sodeifi A, Scrivani SJ et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275-2281.
37. Donnelly JP, Dompeling EC, Meis JF, de-Pauw BE. Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor than antibacterial prophylaxis. Clin Inject Dis 1995; 20: 469-470.
38. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14: 1201-1207.
39. Lucas VS, Beighton D, Roberts GJ, Challacombe SJ. Changes in the oral streptococcal flora of children undergoing allogeneic bone marrow transplantation. J Infect 1997; 35: 135-141.
40. Dompeling EC, Donnelly JP, Raemaekers JM, de-Pauw BE. Pre-emptive administration of corticosteroids prevents the development of ARDS associated with Streptococcus mitis bacteremia following chemotherapy with high-dose cytarabine. Ann Hematol 1994; 69: 69-71.
41. Hall G, Heimdahl A, Nord CE. Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis. Clin Infect Dis 1999; 29: 1-8.
42. Berg RD. Probiotics, prebiotics or 'conbiotics'? Trends Microbiol 1998; 6: 89-92.
43. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-1412.
44. Ferry DM, Butt TJ, Broom MF et al. Bacterial chemotactic oligopeptides and the intestinal mucosal barrier. Gastroenterology 1989; 97: 61-67.
45. Tancrede CH, Andremont AO. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 1985; 152: 99-103.
46. Guzman SG, Bonsack M, Liberty J, Delaney JP. Abdominal radiation causes bacterial translocation. J Surg Res 1989; 46: 104-107.
47. Berg RD. Bacterial translocation from the gastrointestinal tracts of mice receiving immunosuppressive chemotherapeutic agents. Curr Microbiol 1983; 8: 285-292.
48. Wells CL, Maddaus MA, Simmons RL. Proposed mechanisms for the translocation of intestinal bacteria. Rev Infect Dis 1988; 10: 958-979.
49. Alexander JW, Boyce ST, Bubcock GF et al. The process of microbial translocation. Ann Surg 1990; 212: 496-510.
50. van-Leeuwen PA, Boermeester MA, Houdijk AP et al. Clinical significance of translocation. Gut 1994; 35 (Suppl.): S28-S34.
51. O'Dwyer ST, Michie HR, Ziegler TR et al. A single dose of endotoxin increases intestinal permeability in healthy humans. Arch Surg 1988; 123: 1459-1464.
52. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
53. Jackson SK, Parton J, Barnes RA et al. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 1993; 23: 540-545.
54. Schrijver IA, Melief MJ, Eulderink F et al. Bacterial peptidoglycan polysaccharides in sterile human spleen induce proinflammatory cytokine production by human blood cells. J Infect Dis 1999; 179: 1459-1468.
55. Gomez L, Martino R, Rolston KV. Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases. Clin Infect Dis 1998; 27: 695-699.
56. Gorbach SL. Editorial response: neutropenic enterocolitis. Clin Infect Dis 1998; 27: 700-701.
57. Pouwels MJ, Donnelly JP, Raemaekers JM et al. Clostridium septicum sepsis and neutropenic enterocolitis in a patient treated with intensive chemotherapy for acute myeloid leukemia. Ann Hematol 1997; 74: 143-147.
58. Yuen KY, Woo PCY, Liang RHS et al. Clinical significance of alimentary tract microbes in bone marrow transplant recipients. Diagn Microbiol Infect Dis 1998; 30: 75-81.
59. Berkowitz RJ, Strandjord S, Jones P et al. Stomatologic complications of bone marrow transplantation in a pediatric population. Pediatr Dent 1987; 9: 105-110.
60. McDonald GB, Shulman HM, Sullivan KM, Spencer GD. Intestinal and hepatic complications of human bone marrow transplantation. Part II. Gastroenterology 1986; 90: 770-784.
61. Lacy ER. Epithelial restitution in the gastrointestinal tract. J Clin Gastroenterol 1988; 10 (Suppl. 1): S72-S77.
62. Moss SF, Wright NA. Molecular aspects of mucosal repair: a summary (comment). J Biol Med 1996; 69: 155-158.
63. Modlin IM, Poulsom R. Trefoil peptides: mitogens, motogens, or mirages? J Clin Gastroenterol 1997; 25 (Suppl. 1): S94-S100.
64. Podolsky DK. Healing the epithelium: solving the problem from two sides. J Gastroenterol 1997; 32: 122-126.
65. Imamura M, Hashino S, Kobayashi H et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant 1994; 13: 745-751.
66. Pollard M, Chang CF, Srivastava KK. The role of microflora in development of graft-versus-host disease. Transplant Proc 1976; 8: 533-536.
67. van-Bekkum DW, Knaan S. Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst 1977; 58: 787-790.
68. Beelen DW, Elmaagacil A, Müller K-D et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomised trial. Blood 1999; 93: 3267-3275.
69. Travis S, Menzies I. Intestinal permeability: functional assessment and significance. Clin Sci Colch 1992; 82: 471-488.
70. Johansson JE, Ekman T. Gastro-intestinal toxicity related to bone marrow transplantation: disruption of the intestinal barrier precedes clinical findings. Bone Marrow Transplant 1997; 19: 921-925.
71. Selby P, McElwain TJ, Crofts M et at. 51Cr-EDTA test for intestinal permeability. Lancet 1984; 2: 38-39.
72. Rohrbaugh TM, Anolik R, August CS et al. Absorption of oral aminoglycosides following hone marrow transplantation. Cancer 1984; 53: 1502-1506.
73. Ranaldi G, Islam K, Sambuy Y. Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob Agents Chemother 1992; 36: 1374-1381.
74. Meunier V, Bourrie M, Berger Y, Fahre G. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol Toxicol 1995; 11: 187-194.
75. Uil JJ, van-Elburg RM, van-Overbeek FM et al. Clinical implications of the sugar absorption test: intestinal permeability test to assess mucosal barrier function. Scand J Gastroenterol 1997; 223 (Suppl.): 20-28.
76. Parrilli G, Iaffaioli RV, Capuano G et al. Changes in intestinal permeability to lactulose induced by cytotoxic chemotherapy. Cancer Treat Rep 1982; 66: 1435-1436.
77. Parrilli G, Iaffaioli RV, Martorano M et al. Effects of anthra-cycline therapy on intestinal absorption in patients with advanced breast cancer. Cancer Res 1989; 49: 3689-3691.
78. Keefe DM, Cummins AG, Dale BM et al. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci Colch 1997; 92: 385-389.
79. Fegan C, Poynton CH, Whittaker JA. The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant 1990; 5: 373-377.
80. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995; 21: 361-369.
81. Bow EJ, Loewen R, Cheang MS, Shore TB et al. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997; 15: 2254-2261.
82. Sonis ST, Eilers JP, Epstein JB et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer 1999; 85: 2103-2113.
83. Saiki T, Mitsuyama K, Toyonaga A et al. Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 616-622.
84. Wymenga AN, van-der-Graaf WT, Spijkervet FL et al. A new in vitro assay for quantitation of chemotherapy-induced mucositis. Br J Cancer 1997; 76: 1062-1066.
85. Adkins D, Goodgold H, Hendershott L et al. Indium-labeled white blood cells apheresed from donors receiving G-CSF localize to sites of inflammation when infused into allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1997; 19: 809-812.
86. Deitch EA. Bacterial translocation: the influence of dietary variables. Gut 1994; 35 (Suppl.): S23-S27.
87. Papadopoulou A, Williams MD, Darbyshire PJ, Booth IW. Nutritional support in children undergoing bone marrow transplantation. Clin Nutr 1998; 17: 57-63.
88. Papadopoulou A, MacDonald A, Williams MD et al. Enteral nutrition after bone marrow transplantation. Arch Dis Child 1997; 77: 131-136.
89. Ramos MG, Bambirra EA, Cara DC et al. Oral administration of short-chain fatty acids reduces the intestinal mucositis caused by treatment with Ara-C in mice fed commercial or elemental diets. Nutr Cancer 1997; 28: 212-217.
90. Illig KA, Ryan CK, Hardy DJ et al. Total parenteral nutrition-induced changes in gut mucosal function: atrophy alone is not the issue. Surgery 1992; 112: 631-637.
91. Weisdorf SA, Lysne J, Wind D et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 1987; 43: 833-838.
92. Iestra JA, Fibbe WE, Zwinderman AH et al. Parenteral nutrition following intensive cytotoxic therapy: an exploratory study on the need for parenteral nutrition after various treatment approaches for haematological malignancies. Bone Marrow Transplant 1999; 23: 933-939.
93. Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev 1990; 48: 297-309.
94. Karatzas T, Scopa S, Tsoni I et al. Effect of glutamine on intestinal mucosal integrity and bacterial translocation after abdominal radiation. Clin Nutr 1991; 10: 199-205.
95. Klimberg VS, Souba WW, Dolson DJ et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 1990; 66: 62-68.
96. Klimberg VS, Nwokedi E, Hutchins LF et al. Glutamine facilitates chemotherapy while reducing toxicity. J Paren Ent Nutr 1992; 16 (Suppl.): 83S-87S.
97. Anderson PM, Ramsay NKC, Shu XO et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 1998; 22: 339-344.
98. Anderson PM, Schroeder G, Skubitz, KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 1998; 83: 1433-1439.
99. Muscaritoli M, Micozzi A, Conversano L et al. Oral glutamine in the prevention of chemotherapy-induced gastrointestinal toxicity. Eur J Cancer 1997; 33: 319-320.
100. Brown SA, Goringe A, Fegan C et al. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 1998; 22: 281-284.
101. Ziegler TR, Young LS, Benfell K et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 1992; 116: 821-828.
102. Schloerb PR, Skikne BS. Oral and parenteral glutamine in bone marrow transplantation: A randomized, double-blind study. JPEN 1999; 23: 117-122.
103. van-Zaanen HC, van-der-Lelie H, Timmer JG et al. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994; 74: 2879-2884.
104. Franzen L, Henriksson R, Littbrand B, Zackrisson B. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. A double-blind placebo-controlled study. Acta Oncol 1995; 34: 219-223.
105. Makkonen TA, Bostrom P, Vilja P, Joensuu H. Sucralfate mouth washing in the prevention of radiation-induced mucositis: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 1994; 30: 177-182.
106. Barker G, Loftus L, Cuddy P, Barker B. The effects of sucralfate suspension and diphenhydramine syrup plus kaolinpectin on radiotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol 1991; 71: 288-293.
107. Sonis ST, Van-Vugt AG, Brien JP et al. Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 1997; 33: 47-54.
108. Sonis ST, Costa-JW J, Evitts SM et al. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1992; 74: 749-755.
109. Gordon B, Spadinger A, Hodges E et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol 1994; 12: 1917-1922.
110. Ibrahim EM, al-Mulhim FA. Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients. Med Oncol 1997; 14: 47-51.
111. Lieschke GJ, Ramenghi U, O'Connor MP et al. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Haematol 1992; 82: 589-595.
112. Keith-JC J, Albert L, Sonis ST et al. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells 1994; 12 (Suppl. 1): 79-89.
113. Sonis ST, Van-Vugt AG, McDonald J et al. Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine 1997; 9: 605-612.
114. Danilenko DM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol 1999; 27: 64-71.
115. Reilly RM, Domingo R, Sandhu J. Oral delivery of antibodies. Future pharmacokinetic trends. Clin Pharmacokinet 1997; 32: 313-323.
116. Barker GJ. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer 1999; 7: 17-20.
117. Bondi E, Baroni C, Prete A et al. Local antimicrobial therapy of oral mucositis in paediatric patients undergoing bone marrow transplantation. Oral Oncol 1997; 33: 322-326.
118. Ferretti GA, Ash RC, Brown AT et al. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 1987; 114: 461-467.
119. Foote RL, Loprinzi CL, Frank AR et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 1994; 12: 2630-2633.
120. Weisdorf DJ, Bostram B, Raether D et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989; 4: 89-95.
121. Spijkervet FK, van-Saene HK, van-Saene JJ et al. Mucositis prevention by selective elimination of oral flora in irradiated head and neck cancer patients. J Oral Pathol Med 1990; 19: 486-489.
122. Salminen S, Isolauri E, Salminen E. Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Antonie Van Leeuwenhoek 1996; 70: 347-358.
123. Johansson JE, Ekman T. Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study. Bone Marrow Transplant 1999; 24: 35-39.